Abbott (NYSE:ABT) said today that it inked a non-exclusive deal to integrate insulin dose data from Novo Nordisk‘s (NYSE:NVO) pre-filled and connected pens with its FreeStyle Libre mobile app and cloud-based system.
The companies touted that integrating the products will allow healthcare professionals, caregivers and users to easily view glucose and insulin data, as well as make more informed treatment decisions.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.